Palisade Bio (NASDAQ:PALI) Stock Rating Lowered by Wall Street Zen

Palisade Bio (NASDAQ:PALI) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other research analysts also recently commented on the company. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Palisade Bio currently has an average rating of “Hold” and an average price target of $16.00.

Palisade Bio Trading Up 9.6%

Shares of PALI stock opened at $1.83 on Friday. The stock has a market capitalization of $272.67 million, a price-to-earnings ratio of -0.86 and a beta of 1.54. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.59. The stock’s 50-day moving average price is $1.90 and its 200-day moving average price is $1.21.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06). As a group, research analysts predict that Palisade Bio will post -12.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Palisade Bio stock. Armistice Capital LLC grew its position in Palisade Bio, Inc. (NASDAQ:PALI) by 37.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 144,764 shares of the company’s stock after acquiring an additional 39,397 shares during the quarter. Armistice Capital LLC owned about 3.29% of Palisade Bio worth $99,000 at the end of the most recent reporting period. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.